GRML (Greenland Mines) Cyclically Adjusted PS Ratio: (As of Jul. 11, 2026)


GRML Greenland Mines Ltd GRML
12 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is Greenland Mines Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Greenland Mines does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Greenland Mines  (NAS:GRML) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Greenland Mines Cyclically Adjusted PS Ratio Related Terms


Greenland Mines Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Greenland Mines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenland Mines Cyclically Adjusted PS Ratio Chart

Greenland Mines Annual Data
Trend
Cyclically Adjusted PS Ratio

Greenland Mines Semi-Annual Data
Mar25 Mar26
Cyclically Adjusted PS Ratio 0.00 0.00

GRML vs SRGZ, RITE, DYNR: Cyclically Adjusted PS Ratio Comparison

For the Other Precious Metals & Mining subindustry, Greenland Mines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenland Mines Cyclically Adjusted PS Ratio vs Metals & Mining Industry

For the Metals & Mining industry and Basic Materials sector, Greenland Mines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Greenland Mines's Cyclically Adjusted PS Ratio falls into.


GRML
12GF Score
Greenland Mines Ltd GRML
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenland Mines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Greenland Mines does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Greenland Mines Business Description

Address 1300 South Boulevard, Unit D, Charlotte, NC, USA, 28203
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
12GF Score

Get the complete analysis for GRML

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price